Table 3 Data compiled from human studies in inflammation and sepsis

2000

Yokota et al. [34]

In vitro studies of human myeloid cell lines show that adiponectin is a negative regulator of myelomonocytic progenitor growth and downregulates the inflammatory response

2003

Keller et al. [54]

Following induction of endotoxaemia in healthy humans, there was no significant alteration in adiponectin levels (healthy subjects n = 23: 4 females, 19 males)

2006

Tsuchihashi et al. [59]

In vitro studies of recombinant human adiponectin and reconstituted LPS show that adiponectin binds LPS and suppresses LAL

2007

Anderson et al. [55]

No significant alteration in adiponectin levels in endotoxaemia, but downregulation of adiponectin receptor mRNA in white cells (healthy subjects n = 20, 50% male)

2009

Jernås et al. [63]

Lower levels of adiponectin during intensive care stay compared with recovery (subarachnoid haemorrhage n = 8)

2009

Venkatesh et al. [64]

Lower levels of adiponectin in critically ill cohort, with a strong association between plasma cortisol and adiponectin and an inverse correlation between adiponectin and CRP (critically ill n = 20; historical controls n = 16)

2009

Langouche et al. [65]

Lower levels of circulating adiponectin in ICU patients on admission; these levels increased to normal reference values during the ICU stay. Intensive insulin therapy increased the rise of adiponectin over time in ICU. Critically ill n = 318, healthy subjects n = 22, acutely stressed subjects n = 22

2010

Kaplan et al. [69]

Increased levels of HMW adiponectin on day 1 in paediatric septic shock cohort (SIRS/sepsis n = 22, septic shock n = 25, control n = 27)

2010

Hillenbrand et al. [58]

Lower levels of adiponectin in septic patients with negative correlation with SOFA scores (septic shock n = 33, control (blood donors) n = 60, morbidly obese n = 37)

2010

Walkey et al. [68]

Higher levels of adiponectin at baseline associated with increased 28-day mortality (acute respiratory failure n = 175)